Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety and
tolerability of single-dose administration of IDX719 in participants with normal hepatic
function and participants with varying degrees of hepatic impairment.